BOSTON, Sept. 29 /PRNewswire/ -- Paratek Pharmaceuticals, Inc. today
announced the appointment of Malcolm L. Sherman to the Company's Board of
Directors. Paratek is a privately held, pharmaceuticals company engaged in
the development of new anti-infective therapies against drug-resistant
pathogens and therapies for the treatment of serious inflammation-related
diseases for which there are few effective therapies. The appointment of Mr.
Sherman raises the number of Board members at Paratek to nine and is effective
"Malcolm brings substantial financial expertise, and we are pleased that
he has joined our Board," commented Paratek Pharmaceuticals' Chief Executive
Officer, Thomas J. Bigger. "In addition to his successful stewardship of
leading companies in the retail sector, Malcolm has played a prominent role in
the life of the medical community, including his activities as the former
chairman of the board of trustees of Tufts - New England Medical Center and as
a board member of the Whitehead Institute and Massachusetts Eye and Ear, among
others. We believe his expert counsel will greatly aid our transition as we
accelerate the advancement of our breakthrough products."
Mr. Sherman is Chairman of Gordon Brothers, Inc., a Boston-based firm
providing global financial, operating and advisory services to companies at
times of growth or restructuring. During his career, Mr. Sherman has headed
many of the leading firms in his sector, previously holding the positions of
Chairman and CEO at Channel Home Center, Inc., Regina Electric, Inc. and EKCO
Group. He also had a distinguished career at Zayre, attaining the positions
of Executive Vice President at Zayre Corporation and President at Zayre
From 1997 to 2003, Mr. Sherman served as Chairman of the Board of Trustees
of Tufts - New England Medical Center, overseeing the transition of Tufts -
NEMC from the Lifespan system to its original status as an independent, free
standing, not-for-profit teaching hospital. Mr. Sherman remains a governor
and trustee of Tufts - NEMC. He is also Vice Chairman of the board of
trustees at Brandeis University and the past Chairman of the board of trustees
at the Boston Museum of Science, where he remains on the board. Mr. Sherman
is also a board member of Massachusetts Eye and Ear Infirmary, the Molecular
Cardiology Research Institute, Whitehead Institute and Lifespan Corporation.
About Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc. is engaged in the discovery and
commercialization of new therapeutics that treat serious and life-threatening
diseases, with a particular focus on the growing worldwide problem of
antibiotic resistance. Paratek's lead programs are advancing novel compounds
that can circumvent or block bacterial resistance, as well as drugs that can
prevent infection by interfering with Multiple Adaptational Response (MAR)
mechanisms in bacteria. Out of these efforts, Paratek has discovered a new
class of antibiotics, the aminomethylcyclines (including BAY 73-7388) that
target the need for new and potent antibacterials to overcome the problem of
rapidly growing bacterial resistance. BAY 73-7388 is being developed in a
collaborative partnership with Bayer HealthCare AG for the treatment of
Outside the antibacterial therapeutic area, Paratek has also established
an internal effort to exploit the Company's novel family of compounds and
their unique mechanism of action in selected anti-inflammatory and
neurodegenerative conditions. Paratek has an active chemical synthesis effort
within this family of compounds to produce novel and diverse small molecules,
with the goal of developing non-antibacterial products with improved activity
in serious diseases based upon a growing body of clinical and basic research
supporting this approach.
Paratek is privately held and headquartered in Boston, Massachusetts, USA.
For more information, visit Paratek's website at http://www.paratekpharm.com.
SOURCE Paratek Pharmaceuticals, Inc.